|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
EP3455218A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
WO2017197036A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
WO2018053354A1
(en)
|
2016-09-15 |
2018-03-22 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
JP2019537585A
(ja)
|
2016-10-28 |
2019-12-26 |
アイカーン スクール オブ メディスン アット マウント シナイ |
Ｅｚｈ２媒介性がんを治療するための組成物および方法
|
|
KR20230127371A
(ko)
|
2016-11-01 |
2023-08-31 |
아비나스 오퍼레이션스, 인코포레이티드 |
타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
|
|
IL297717A
(en)
|
2016-12-01 |
2022-12-01 |
Arvinas Operations Inc |
History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
WO2018119441A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Egfr proteolysis targeting chimeric molecules and associated methods of use
|
|
MX2019007649A
(es)
|
2016-12-23 |
2019-09-10 |
Arvinas Operations Inc |
Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente.
|
|
WO2018118598A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
|
EP3577109A4
(en)
|
2017-01-31 |
2020-11-18 |
Arvinas Operations, Inc. |
CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
|
|
KR102014478B1
(ko)
*
|
2017-05-12 |
2019-08-26 |
한국화학연구원 |
신규한 피페리딘-2,6-디온 유도체 및 이의 용도
|
|
CN118440096A
(zh)
|
2017-06-20 |
2024-08-06 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
US10357489B2
(en)
|
2017-07-10 |
2019-07-23 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
WO2019043208A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROQUINOLINONES
|
|
CN111315735B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
二氢苯并咪唑酮
|
|
EP3679026A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Glutarimide
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
|
CN111372585A
(zh)
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3743066A4
(en)
|
2018-01-26 |
2021-09-08 |
Yale University |
IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE
|
|
US11028088B2
(en)
|
2018-03-10 |
2021-06-08 |
Yale University |
Modulators of BTK proteolysis and methods of use
|
|
KR20210018199A
(ko)
|
2018-03-26 |
2021-02-17 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스의 분해를 위한 세레블론 결합제
|
|
EP3774804A1
(en)
|
2018-03-26 |
2021-02-17 |
Novartis AG |
N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
|
|
MX2020010368A
(es)
|
2018-04-01 |
2021-01-08 |
Arvinas Operations Inc |
Compuestos dirigidos a brm y métodos de uso asociados.
|
|
JP7720698B2
(ja)
|
2018-04-04 |
2025-08-08 |
アルビナス・オペレーションズ・インコーポレイテッド |
タンパク質分解の調節因子および関連する使用方法
|
|
EP3774772A1
(en)
*
|
2018-04-13 |
2021-02-17 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2019204354A1
(en)
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
|
EP4272737A3
(en)
|
2018-04-23 |
2024-01-17 |
Celgene Corporation |
Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
|
|
US20190375732A1
(en)
|
2018-05-14 |
2019-12-12 |
David Hung |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
AU2019294836B2
(en)
|
2018-06-29 |
2024-06-20 |
Dana-Farber Cancer Institute, Inc. |
Bispecific degraders
|
|
CN113166100A
(zh)
|
2018-06-29 |
2021-07-23 |
达纳-法伯癌症研究所有限公司 |
免疫调节性化合物
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CA3103385A1
(en)
|
2018-07-10 |
2020-01-16 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
|
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
|
EP3831811A4
(en)
|
2018-07-31 |
2022-04-20 |
Fimecs, Inc. |
HETEROCYCLIC COMPOUND
|
|
CN108774215A
(zh)
*
|
2018-08-15 |
2018-11-09 |
翟学旭 |
含氮杂环类衍生物及其在视网膜新生血管疾病中的应用
|
|
CN112912376A
(zh)
|
2018-08-20 |
2021-06-04 |
阿尔维纳斯运营股份有限公司 |
用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
|
|
CA3110267A1
(en)
|
2018-08-22 |
2020-02-27 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (trk) degradation compounds and methods of use
|
|
US11969472B2
(en)
|
2018-08-22 |
2024-04-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
EP3846800A4
(en)
|
2018-09-04 |
2022-08-24 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
EP3848371A4
(en)
*
|
2018-09-07 |
2022-06-08 |
Medshine Discovery Inc. |
TRICYCLIC FURAN-SUBSTITUTED PIPERIDONEE COMPOUND
|
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
CN113490495B
(zh)
*
|
2018-12-03 |
2024-09-27 |
达纳-法伯癌症研究公司 |
Helios的小分子降解剂及其使用方法
|
|
FI3897636T3
(fi)
|
2018-12-19 |
2025-02-03 |
Celgene Corp |
Substituoituja 3-((3-aminofenyyli)amino)piperidiini-2,6-dioniyhdisteitä, niiden koostumuksia ja menetelmiä niillä annettavia hoitoja varten
|
|
KR102864064B1
(ko)
|
2018-12-19 |
2025-09-24 |
셀진 코포레이션 |
치환된 3-((3-아미노페닐)아미노)피페리딘-2,6-디온 화합물, 이의 조성물, 및 이를 사용한 치료 방법
|
|
CN120698985A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
US11098025B2
(en)
*
|
2019-01-30 |
2021-08-24 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
WO2020162725A1
(ko)
*
|
2019-02-07 |
2020-08-13 |
한국화학연구원 |
표적 단백질 ｅｅｄ 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 ｅｅｄ, ｅｚｈ2, 또는 ｐｒｃ2 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
ES2982474T3
(es)
|
2019-02-15 |
2024-10-16 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
|
|
US20220143183A1
(en)
*
|
2019-02-23 |
2022-05-12 |
New York University |
Photoswitchable protacs and synthesis and uses thereof
|
|
SG11202110829YA
(en)
|
2019-04-05 |
2021-10-28 |
Kymera Therapeutics Inc |
Stat degraders and uses thereof
|
|
WO2020206608A1
(en)
*
|
2019-04-09 |
2020-10-15 |
Ranok Therapeutics (Hangzhou) Co., Ltd. |
Methods and compositions for targeted protein degradation
|
|
WO2020214555A1
(en)
|
2019-04-16 |
2020-10-22 |
Northwestern University |
Bifunctional compounds comprising apcin-a and their use in the treatment of cancer
|
|
CN111825657A
(zh)
*
|
2019-04-18 |
2020-10-27 |
成都海创药业有限公司 |
一类靶向降解雄激素受体的双功能嵌合体杂环化合物及其用途
|
|
CN114423463B
(zh)
|
2019-05-06 |
2025-09-26 |
西奈山伊坎医学院 |
作为hpk1的降解剂的异双功能化合物
|
|
KR20220008869A
(ko)
|
2019-05-14 |
2022-01-21 |
누베이션 바이오 인크. |
항암 핵 호르몬 수용체-표적화 화합물
|
|
US20230087825A1
(en)
*
|
2019-06-10 |
2023-03-23 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020252397A1
(en)
*
|
2019-06-12 |
2020-12-17 |
Baylor College Of Medicine |
Small molecule proteolysis-targeting chimeras and methods of use thereof
|
|
PE20220231A1
(es)
|
2019-06-25 |
2022-02-07 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso
|
|
US11912699B2
(en)
|
2019-07-17 |
2024-02-27 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated
|
|
EP4021450B1
(en)
|
2019-08-26 |
2025-11-05 |
Arvinas Operations, Inc. |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
WO2021041664A1
(en)
*
|
2019-08-27 |
2021-03-04 |
The Regents Of The University Of Michigan |
Cereblon e3 ligase inhibitors
|
|
CN114401962B
(zh)
*
|
2019-09-12 |
2024-05-24 |
南京明德新药研发有限公司 |
作为crbn蛋白调节剂的双并环类化合物
|
|
TW202123942A
(zh)
*
|
2019-09-16 |
2021-07-01 |
瑞士商諾華公司 |
Ｂｒｄ９雙官能基降解劑及其使用方法
|
|
WO2021053555A1
(en)
*
|
2019-09-16 |
2021-03-25 |
Novartis Ag |
Glue degraders and methods of use thereof
|
|
WO2021067606A1
(en)
|
2019-10-01 |
2021-04-08 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
AU2020368542B2
(en)
|
2019-10-17 |
2024-02-29 |
Arvinas Operations, Inc. |
Bifunctional molecules containing an E3 ubiquitine ligase binding moiety linked to a BCL6 targeting moiety
|
|
TW202131930A
(zh)
|
2019-11-13 |
2021-09-01 |
美商諾維雪碧歐公司 |
抗癌核荷爾蒙受體標靶化合物
|
|
CN110885332B
(zh)
*
|
2019-12-06 |
2022-03-18 |
中国人民解放军第二军医大学 |
一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用
|
|
GB201918414D0
(en)
*
|
2019-12-13 |
2020-01-29 |
Z Factor Ltd |
Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
|
|
EP4076520A4
(en)
|
2019-12-17 |
2024-03-27 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US20230020607A1
(en)
*
|
2019-12-17 |
2023-01-19 |
Orionis Biosciences, Inc. |
Modulation of protein degradation
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
AU2020405129A1
(en)
|
2019-12-19 |
2022-06-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
MX2022007659A
(es)
|
2019-12-20 |
2022-07-19 |
C4 Therapeutics Inc |
Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr).
|
|
BR112022012410A2
(pt)
|
2019-12-23 |
2022-08-30 |
Kymera Therapeutics Inc |
Degradadores smarca e usos dos mesmos
|
|
PE20230114A1
(es)
|
2019-12-23 |
2023-01-27 |
Shanghai Jemincare Pharmaceuticals Co Ltd |
Metodo y aplicacion de preparacion de compuesto como agente de degradacion de proteinas
|
|
CN115190804A
(zh)
*
|
2020-01-14 |
2022-10-14 |
纽约市哥伦比亚大学理事会 |
通过重定向内源性去泛素化酶稳定靶向蛋白质的组合物和方法
|
|
WO2021143816A1
(zh)
*
|
2020-01-16 |
2021-07-22 |
江苏恒瑞医药股份有限公司 |
稠合酰亚胺类衍生物、其制备方法及其在医药上的应用
|
|
TW202140448A
(zh)
*
|
2020-01-16 |
2021-11-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
並環醯亞胺類衍生物、其製備方法及其在醫藥上的應用
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
BR112022014623A2
(pt)
|
2020-02-14 |
2022-09-13 |
Jounce Therapeutics Inc |
Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
CN115697989B
(zh)
|
2020-02-26 |
2025-03-18 |
上海睿跃生物科技有限公司 |
原肌球蛋白受体激酶(trk)降解化合物和使用方法
|
|
EP3875456A1
(en)
*
|
2020-03-02 |
2021-09-08 |
Technische Universität Darmstadt |
Hetero-bifunctional proteolysis-targeting chimeras (protacs) for the selective degradation of fk506-binding proteins (fkbps)
|
|
AU2021231898A1
(en)
|
2020-03-05 |
2022-10-27 |
C4 Therapeutics, Inc. |
Compounds for targeted degradation of BRD9
|
|
CN111249276B
(zh)
*
|
2020-03-05 |
2021-07-13 |
南京巴傲得生物科技有限公司 |
吲哚布洛芬制备cbp溴区抑制试剂的用途
|
|
US20230123104A1
(en)
*
|
2020-03-06 |
2023-04-20 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Crystal of tricyclic compound acting on crbn protein and preparation method therefor
|
|
CN113387931A
(zh)
*
|
2020-03-13 |
2021-09-14 |
四川海思科制药有限公司 |
一种具有抑制或降解蛋白激酶的化合物及其制备方法和药学上的应用
|
|
WO2021185291A1
(zh)
*
|
2020-03-17 |
2021-09-23 |
南京明德新药研发有限公司 |
蛋白降解调节剂与其使用方法
|
|
CA3171337A1
(en)
*
|
2020-03-18 |
2021-09-23 |
Dana-Farber Cancer Institute, Inc. |
Targeted degraders of aberrant tau based on the pet tracer pbb3
|
|
PH12022552458A1
(en)
|
2020-03-19 |
2024-01-22 |
Kymera Therapeutics Inc |
Mdm2 degraders and uses thereof
|
|
KR20210122163A
(ko)
*
|
2020-03-27 |
2021-10-08 |
(주) 업테라 |
Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
|
|
WO2021210878A1
(ko)
*
|
2020-04-17 |
2021-10-21 |
광주과학기술원 |
Crbn 결합 펩티드 및 이를 이용한 알츠하이머 병 예방 또는 치료용 조성물
|
|
WO2021219077A1
(zh)
*
|
2020-04-29 |
2021-11-04 |
泰比棣医药科技(石家庄)有限公司 |
一种组织靶向的蛋白靶向降解化合物及其用途
|
|
CN113582974B
(zh)
*
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
WO2021231927A1
(en)
*
|
2020-05-14 |
2021-11-18 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders with a tricyclic cereblon ligand
|
|
CA3172589A1
(en)
*
|
2020-05-21 |
2021-11-25 |
Dana-Farber Cancer Institute, Inc. |
Piperidine-2,6-diones as small molecule degraders of helios and methods of use
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
CN116082311B
(zh)
*
|
2020-06-12 |
2025-04-25 |
上海济煜医药科技有限公司 |
酞嗪酮类化合物及其制备方法和医药用途
|
|
AU2021296165A1
(en)
*
|
2020-06-22 |
2022-11-24 |
Dana-Farber Cancer Institute, Inc. |
Protein tag to induce ligand dependent degradation of protein/protein-fusions
|
|
KR102559329B1
(ko)
*
|
2020-07-02 |
2023-07-25 |
포항공과대학교 산학협력단 |
신규한 프로탁 키메라 화합물, 이를 포함하는 표적 단백질 분해를 통한 질환의 예방, 개선 또는 치료용 약학적 조성물
|
|
EP4180427A4
(en)
*
|
2020-07-09 |
2024-08-21 |
Xizang Haisco Pharmaceutical Co., Ltd. |
COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS AND PHARMACEUTICAL COMPOSITIONS AND THEIR PHARMACEUTICAL USES
|
|
CA3186548A1
(en)
*
|
2020-07-21 |
2022-01-27 |
Song Hee Lee |
Compound for androgen receptor degradation, and pharmaceutical use thereof
|
|
KR20220014952A
(ko)
*
|
2020-07-29 |
2022-02-08 |
한국화학연구원 |
안드로겐 수용체의 저해 또는 분해용 화합물 및 이들의 의약 용도
|
|
BR112023001956A2
(pt)
*
|
2020-08-03 |
2023-02-28 |
Captor Therapeutics S A |
Composto de fórmula (ia), (ib), (ic) ou (ii), composição farmacêutica, composto para uso ou composição farmacêutica para uso em um método de tratamento de câncer
|
|
JP2023538517A
(ja)
|
2020-08-05 |
2023-09-08 |
シーフォー セラピューティクス， インコーポレイテッド |
Ｒｅｔの標的分解のための化合物
|
|
EP4194457A4
(en)
*
|
2020-08-05 |
2024-08-07 |
Shanghai Leadingtac Pharmaceutical Co., Ltd. |
COMPOUND FOR TARGETING AND DEGRADING A PROTEIN, ITS PREPARATION METHOD AND ITS USE
|
|
EP4204418A1
(en)
|
2020-08-28 |
2023-07-05 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
CN114133379B
(zh)
*
|
2020-09-04 |
2024-02-13 |
南京奥瑞药业有限公司 |
一种杂环化合物、其制备方法、中间体、组合物以及应用
|
|
CN114163444B
(zh)
*
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
EP4211128A1
(en)
|
2020-09-14 |
2023-07-19 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
CN114181277A
(zh)
*
|
2020-09-15 |
2022-03-15 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
EP4217352A4
(en)
|
2020-09-23 |
2024-04-10 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
|
|
BR112023005708A2
(pt)
*
|
2020-09-30 |
2023-05-02 |
Astrazeneca Ab |
Compostos e seu uso no tratamento do câncer
|
|
CA3194351A1
(en)
*
|
2020-10-14 |
2022-04-21 |
Christopher G. Nasveschuk |
Tricyclic compounds to degrade neosubstrates for medical therapy
|
|
KR20230111615A
(ko)
|
2020-10-21 |
2023-07-25 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체 단백질의 표적화된 분해를 위한 화합물 및 방법
|
|
CN114621231B
(zh)
*
|
2020-12-14 |
2025-09-12 |
杭州中美华东制药有限公司 |
一种靶向降解/抑制活性的嵌合化合物及其制备方法和用途
|
|
TW202241891A
(zh)
|
2020-12-30 |
2022-11-01 |
美商凱麥拉醫療公司 |
Irak降解劑及其用途
|
|
WO2022152821A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
|
CN116867778A
(zh)
*
|
2021-02-04 |
2023-10-10 |
正大天晴药业集团股份有限公司 |
苯并七元环类双功能化合物及其应用
|
|
JP2024506656A
(ja)
|
2021-02-15 |
2024-02-14 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその使用
|
|
US20240383868A1
(en)
*
|
2021-02-19 |
2024-11-21 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2022195355A1
(en)
*
|
2021-03-15 |
2022-09-22 |
Novartis Ag |
Benzisoxazole derivatives and uses thereof
|
|
BR112023019420A2
(pt)
|
2021-03-23 |
2023-10-24 |
Nuvation Bio Inc |
Compostos de direcionamento ao receptor de hormônio nuclear anticâncer
|
|
CA3211378A1
(en)
*
|
2021-03-29 |
2022-10-06 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicine
|
|
CN115141179B
(zh)
*
|
2021-03-31 |
2024-09-13 |
江苏恒瑞医药股份有限公司 |
一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用
|
|
US20240217968A1
(en)
*
|
2021-03-31 |
2024-07-04 |
Duke Street Bio Limited |
Pharmaceutical compound
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
EP4323352A1
(en)
|
2021-04-16 |
2024-02-21 |
Arvinas Operations, Inc. |
Modulators of bcl6 proteolysis and associated methods of use
|
|
CN113603676B
(zh)
*
|
2021-04-28 |
2022-05-24 |
浙江工业大学 |
基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用
|
|
EP4334314A1
(en)
*
|
2021-05-03 |
2024-03-13 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CA3217417A1
(en)
|
2021-05-05 |
2022-11-10 |
Kevin M. Guckian |
Compounds for targeting degradation of bruton's tyrosine kinase
|
|
US12097261B2
(en)
|
2021-05-07 |
2024-09-24 |
Kymera Therapeutics, Inc. |
CDK2 degraders and uses thereof
|
|
US20220389394A1
(en)
|
2021-05-18 |
2022-12-08 |
Gilead Sciences, Inc. |
METHODS OF USING FLT3L-Fc FUSION PROTEINS
|
|
EP4116298A4
(en)
*
|
2021-05-26 |
2023-06-28 |
Innocure Therapeutics, Inc. |
Piperidinedione derivative
|
|
KR102489160B1
(ko)
*
|
2021-05-26 |
2023-01-18 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
KR102474999B1
(ko)
*
|
2021-05-26 |
2022-12-07 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
WO2022250350A1
(ko)
*
|
2021-05-26 |
2022-12-01 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
WO2022255889A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022255890A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022255888A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
MX2023014059A
(es)
|
2021-06-08 |
2024-03-12 |
C4 Therapeutics Inc |
Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
|
|
JP2024526191A
(ja)
*
|
2021-06-25 |
2024-07-17 |
セルジーン コーポレーション |
セレブロン結合化合物、その組成物及びそれによる治療方法
|
|
US20250100995A1
(en)
*
|
2021-06-25 |
2025-03-27 |
Celgene Corporation |
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
|
|
WO2022272061A1
(en)
*
|
2021-06-25 |
2022-12-29 |
Celgene Corporation |
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
|
|
WO2023283130A1
(en)
|
2021-07-04 |
2023-01-12 |
Newave Pharmaceutical Inc. |
Isoquinoline derivatives as mutant egfr modulators and uses thereof
|
|
AU2022308734A1
(en)
|
2021-07-07 |
2024-02-22 |
Biogen Ma Inc. |
Compounds for targeting degradation of irak4 proteins
|
|
US20250018046A1
(en)
|
2021-07-07 |
2025-01-16 |
Biogen Ma Inc |
Compounds for targeting degradation of irak4 proteins
|
|
WO2023283425A1
(en)
|
2021-07-09 |
2023-01-12 |
Plexium, Inc. |
Aryl compounds and pharmaceutical compositions that modulate ikzf2
|
|
WO2023017442A1
(en)
*
|
2021-08-10 |
2023-02-16 |
Uppthera, Inc. |
Novel plk1 degradation inducing compound
|
|
WO2023016518A1
(zh)
*
|
2021-08-11 |
2023-02-16 |
四川海思科制药有限公司 |
一种杂环衍生物及其组合物和药学上的应用
|
|
PT4367118T
(pt)
|
2021-08-18 |
2025-04-16 |
Gilead Sciences Inc |
Degradadores bifuncionais de quinases associadas ao recetor de interleucina-1 e sua utilização terapêutica
|
|
WO2023025159A1
(zh)
*
|
2021-08-23 |
2023-03-02 |
上海领泰生物医药科技有限公司 |
Irak4降解剂及其制备方法和应用
|
|
WO2023034411A1
(en)
|
2021-09-01 |
2023-03-09 |
Oerth Bio Llc |
Compositions and methods for targeted degradation of proteins in a plant cell
|
|
CN115746058A
(zh)
*
|
2021-09-03 |
2023-03-07 |
南京知和医药科技有限公司 |
一种多环化合物在制备抗肿瘤药物方面的用途
|
|
WO2023056443A1
(en)
*
|
2021-10-01 |
2023-04-06 |
Dana-Farber Cancer Institute, Inc. |
Binders of cereblon and methods of use thereof
|
|
TW202322799A
(zh)
*
|
2021-10-06 |
2023-06-16 |
美商Ｃ４醫藥公司 |
冠狀病毒非結構性蛋白3降解化合物
|
|
EP4421071A1
(en)
*
|
2021-10-22 |
2024-08-28 |
Gluetacs Therapeutics (Shanghai) Co., Ltd. |
Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications
|
|
AU2022375782A1
(en)
|
2021-10-28 |
2024-05-02 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
WO2023076556A1
(en)
|
2021-10-29 |
2023-05-04 |
Kymera Therapeutics, Inc. |
Irak4 degraders and synthesis thereof
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
WO2023081224A1
(en)
*
|
2021-11-03 |
2023-05-11 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4- yl)methyl)benzamide analogs as modulators of cereblon protein
|
|
WO2023081452A1
(en)
*
|
2021-11-05 |
2023-05-11 |
University Of South Carolina |
Small-molecule degraders of cdk8 and cdk19
|
|
US20250059198A1
(en)
|
2021-11-24 |
2025-02-20 |
Arvinas Operations, Inc. |
Brm degrading compounds and associated methods of use
|
|
EP4436965A1
(en)
|
2021-11-24 |
2024-10-02 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
WO2023093845A1
(zh)
|
2021-11-25 |
2023-06-01 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
CA3237577A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4452414A2
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN114085213B
(zh)
*
|
2022-01-20 |
2022-03-25 |
苏州国匡医药科技有限公司 |
一种arv-471的制备方法
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
JP2025504059A
(ja)
|
2022-01-31 |
2025-02-06 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋデグレーダー及びその使用
|
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4499628A1
(en)
*
|
2022-03-24 |
2025-02-05 |
GlaxoSmithKline Intellectual Property Development Limited |
2,4-dioxotetrahydropyrimidinyl derivatives as degrons in protacs
|
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2023212599A2
(en)
*
|
2022-04-26 |
2023-11-02 |
Endotarget Inc. |
Compounds and methods for targeted degradation of estrogen receptors
|
|
IL316803A
(en)
|
2022-06-06 |
2025-01-01 |
C4 Therapeutics Inc |
Bicyclic glutarimide-modified cervalon-binding agents
|
|
TWI893405B
(zh)
*
|
2022-06-30 |
2025-08-11 |
安宏生醫股份有限公司 |
雙官能基化合物及包含該雙官能基化合物之醫藥組成物，及其用於製備治療雄激素受體相關疾病之藥物的用途
|
|
CA3260083A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences Inc |
CD73 COMPOUNDS
|
|
WO2024015412A1
(en)
*
|
2022-07-12 |
2024-01-18 |
Regents Of The University Of Michigan |
Tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
CN116496253B
(zh)
*
|
2022-08-19 |
2024-10-11 |
中国人民解放军军事科学院军事医学研究院 |
c-MET蛋白靶向降解剂及其医药应用
|
|
CN115089588A
(zh)
*
|
2022-08-22 |
2022-09-23 |
云南大学 |
达沙布韦作为e3连接酶新型配体构建protac的应用
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
TW202432544A
(zh)
|
2022-09-07 |
2024-08-16 |
美商亞文納營運公司 |
快速加速纖維肉瘤降解化合物及相關使用方法
|
|
CN118019736A
(zh)
*
|
2022-09-08 |
2024-05-10 |
标新生物医药科技(上海)有限公司 |
基于cereblon蛋白设计的分子胶化合物及其应用
|
|
WO2024054954A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024054955A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024054953A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
IL319458A
(en)
|
2022-09-09 |
2025-05-01 |
Innovo Therapeutics Inc |
Compounds that reduce ck1α and dual ck1α/gspt1
|
|
WO2024056005A1
(zh)
*
|
2022-09-14 |
2024-03-21 |
先声再明医药有限公司 |
多并环类化合物及其用途
|
|
WO2024064316A1
(en)
|
2022-09-23 |
2024-03-28 |
Regents Of The University Of Michigan |
Compounds and compositions as smarca2/4 inhibitors and uses thereof
|
|
WO2024073475A1
(en)
*
|
2022-09-27 |
2024-04-04 |
Oncopia Therapeutics, Inc. D/B/A Proteovant Therapeutics, Inc. |
Cereblon ligands and uses thereof
|
|
CN120035586A
(zh)
*
|
2022-09-29 |
2025-05-23 |
江苏恒瑞医药股份有限公司 |
一种四氢萘类衍生物的可药用盐、晶型及制备方法
|
|
CN119998300A
(zh)
*
|
2022-09-29 |
2025-05-13 |
海南先声再明医药股份有限公司 |
一类稠环化合物及其用途
|
|
CN117801051A
(zh)
*
|
2022-09-30 |
2024-04-02 |
苏州德亘生物医药有限公司 |
一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物
|
|
TW202425994A
(zh)
|
2022-10-24 |
2024-07-01 |
美商亞文納營運公司 |
用於靶向降解雄激素受體之化合物及方法
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
JP2025538555A
(ja)
*
|
2022-11-22 |
2025-11-28 |
イノキュア セラピューティクス，インコーポレイテッド |
新規のｃ－ｍｅｔタンパク質リガンドを含む分解剤およびそれを含む薬学的組成物
|
|
WO2024112119A1
(ko)
*
|
2022-11-22 |
2024-05-30 |
주식회사 이노큐어테라퓨틱스 |
cMET 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물
|
|
EP4640686A1
(en)
*
|
2022-11-22 |
2025-10-29 |
Innocure Therapeutics, Inc. |
Degrader for degrading brd protein and pharmaceutical composition containing same
|
|
AU2023389065A1
(en)
*
|
2022-12-06 |
2025-06-19 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
WO2024123195A1
(en)
*
|
2022-12-06 |
2024-06-13 |
Captor Therapeutics S.A. |
Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
US20240254118A1
(en)
|
2022-12-22 |
2024-08-01 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024153025A1
(zh)
*
|
2023-01-16 |
2024-07-25 |
南京明德新药研发有限公司 |
取代的苯并七元环化合物及其应用
|
|
TW202444727A
(zh)
|
2023-01-26 |
2024-11-16 |
美商艾維納斯手術有限公司 |
基於cereblon之kras降解protac及其相關用途
|
|
CN120677148A
(zh)
*
|
2023-02-16 |
2025-09-19 |
百时美施贵宝公司 |
作为ret激酶降解剂的异吲哚啉酮戊二酰亚胺和苯基戊二酰亚胺类似物
|
|
CN116253719B
(zh)
*
|
2023-03-06 |
2025-04-01 |
苏州国匡医药科技有限公司 |
一种雌激素和雄激素受体双重降解剂及其应用
|
|
TW202508568A
(zh)
|
2023-04-07 |
2025-03-01 |
瑞典商阿斯特捷利康公司 |
Ｉｒａｋ４蛋白水解靶向嵌合體
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024256729A1
(en)
*
|
2023-04-20 |
2025-09-25 |
Auron Therapeutics, Inc. |
Technologies targeting cell states
|
|
CN121079300A
(zh)
|
2023-04-21 |
2025-12-05 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
WO2024243441A1
(en)
|
2023-05-24 |
2024-11-28 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2024245408A1
(zh)
*
|
2023-06-01 |
2024-12-05 |
上海海和药物研究开发股份有限公司 |
用于雄激素受体依赖性疾病的苯并(杂)环烷基化合物
|
|
CN120202200A
(zh)
*
|
2023-06-01 |
2025-06-24 |
标新生物医药科技(上海)有限公司 |
基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
|
|
CN119451952A
(zh)
*
|
2023-06-01 |
2025-02-14 |
标新生物医药科技(上海)有限公司 |
氧代异吲哚啉基取代的四氢嘧啶二酮衍生物及其应用
|
|
WO2024256988A1
(en)
|
2023-06-14 |
2024-12-19 |
Astrazeneca Ab |
Smarca2 degraders and uses thereof
|
|
UY40785A
(es)
|
2023-06-14 |
2024-12-31 |
Astrazeneca Ab |
Degradadores de smarca2 y usos de los mismos antecedentes
|
|
WO2024263781A1
(en)
*
|
2023-06-23 |
2024-12-26 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Targeted degraders of hiv-1 nef for the treatment of hiv disease
|
|
WO2025006783A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras
|
|
WO2025006753A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|
|
WO2025006720A1
(en)
|
2023-06-30 |
2025-01-02 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025007000A1
(en)
|
2023-06-30 |
2025-01-02 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
WO2025011623A1
(zh)
*
|
2023-07-12 |
2025-01-16 |
上海壹迪生物技术有限公司 |
氰基喹啉类靶向蛋白降解分子、其制备方法和应用
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025056073A1
(zh)
*
|
2023-09-14 |
2025-03-20 |
中国科学院上海药物研究所 |
吲唑酮类化合物、其制备方法、药物组合物及其应用
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
WO2025061906A1
(en)
*
|
2023-09-22 |
2025-03-27 |
Glaxosmithkline Intellectual Property Development Limited |
Androgen receptor protacs
|
|
WO2025075693A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Purdue Research Foundation |
Shp2 degraders for cancer therapy
|
|
WO2025096855A1
(en)
|
2023-11-02 |
2025-05-08 |
Kumquat Biosciences Inc. |
Degraders and uses thereof
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025114875A1
(en)
*
|
2023-12-01 |
2025-06-05 |
Astrazeneca Ab |
Er degraders and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025136129A1
(en)
*
|
2023-12-22 |
2025-06-26 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target protein kinase c
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025212557A1
(en)
*
|
2024-04-01 |
2025-10-09 |
The Johns Hopkins University |
Delivery of aurora kinase inhibitors using nano-scale drug delivery platforms by covalent conjugation
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|